“So as we look ahead, we expect the combination of this data, coupled with the global rollout of Evolut FX to drive our TAVR growth above market.”

In context

“initial procedure. And last month our landmark Evolut low-risk trial was presented at TCT and published in Jack. The trial randomized patients to Evolut or best-in-class surgery. As you can see in this chart, Evolut, which is the blue line, had a lower rate of death or disabling stroke, and the difference continues to diverge each year, going from a 2% difference at two years to 2.9% at three years and growing to a 3.4% difference at four years. This resulted in a 26% reduction in death or disabling stroke with Evolut at four years. And no other transcatheter valve has shown better valve performance and outcomes, compared to surgery. Valve design matters and this differentiates us competitively. Physicians understand this data. This is compelling to them, and it's compelling to patients. So as we look ahead, we expect the combination of this data, coupled with the global rollout of Evolut FX to drive our TAVR growth above market. In neurovascular, we grew high-single-digits when you exclude sales in China where the coils market is subject to volume-based procurement. We continue to see very strong growth and flow diversion, which was up low-20s globally. This is being driven by our innovative Shield Technology for treating brain aneurysms, which is available on both the Pipeline Flex and Pipeline Vantage flow diverters. In Robotic Surgical Technologies, we increased our installed base as we continue the international launch of our differentiated Hugo robotic system. In the U.S., our EXPAND URO pivotal trial continues to enroll and is on plan. And we're happy to announce that we have FDA approval to start our U.S. Hernia indication pivotal trial for Hugo. Adoption of Hugo is positive, with surgeons appreciating fea”